Comparison of different tyrosine kinase inhibitors for treatment of poor performance status patients with EGFR-mutated lung adenocarcinoma
CE Wu, CF Chang, CY Huang, CT Yang, CHS Kuo… - Cancers, 2022 - mdpi.com
Simple Summary Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)
are standard treatments in patients with EGFR-mutated lung adenocarcinoma. However, the …
are standard treatments in patients with EGFR-mutated lung adenocarcinoma. However, the …
Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with …
H Li, C Wang, Z Wang, Y Hu, G Zhang, M Zhang… - Lung Cancer, 2019 - Elsevier
Purpose This study aims to understand the effects and long-term survival of 1st generation
epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) or platinum-based …
epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) or platinum-based …
Survival‑associated factors of first‑line EGFR‑tyrosine kinase inhibitor responders and non‑responders in lung adenocarcinoma patients with common EGFR …
MS Hung, YH Fang, YC Lin… - Molecular and …, 2018 - spandidos-publications.com
The aim of the present retrospective cohort study was to elucidate the clinical presentation of
epidermal growth factor receptor (EGFR)‑tyrosine kinase inhibitor (TKI) responders and non …
epidermal growth factor receptor (EGFR)‑tyrosine kinase inhibitor (TKI) responders and non …
Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors …
S Pilotto, M Di Maio, U Peretti, S Kinspergher… - Critical Reviews in …, 2014 - Elsevier
Purpose We performed a sensitivity and meta-regression analysis, cumulating all
randomized trials exploring the benefit of afatinib, erlotinib and gefitinib versus …
randomized trials exploring the benefit of afatinib, erlotinib and gefitinib versus …
Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma …
Background Mutations in the epidermal growth factor receptor (EGFR) have been
associated with a marked therapeutic response to EGFR-tyrosine kinase inhibitors (TKIs) in …
associated with a marked therapeutic response to EGFR-tyrosine kinase inhibitors (TKIs) in …
[PDF][PDF] Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors …
Purpose We examined the impact of different epidermal growth factor receptor (EGFR)
mutations and clinical characteristics on progression-free survival (PFS) in patients with …
mutations and clinical characteristics on progression-free survival (PFS) in patients with …
EGFR–TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation
DH Koo, K Kim, CM Choi, DH Lee, JC Lee… - Cancer chemotherapy …, 2015 - Springer
Purpose Although epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR–TKIs)
have become key therapeutic agents for non-small cell lung cancer (NSCLC) patients with …
have become key therapeutic agents for non-small cell lung cancer (NSCLC) patients with …
Subsequent treatment of epidermal growth factor receptor‐tyrosine kinase inhibitor failure in patients with advanced lung adenocarcinoma
X Qiao, Y Zhang, J Wang, J Nong, X Li, X Yang… - Thoracic …, 2015 - Wiley Online Library
Background Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs)
effectively treat advanced non‐small cell lung cancer with EGFR‐mutation. However, most …
effectively treat advanced non‐small cell lung cancer with EGFR‐mutation. However, most …
First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution's clinical practice experience
X Yu, X Zhang, Z Zhang, Y Lin, Y Wen, Y Chen… - Cancer …, 2018 - Springer
Background The antitumour efficacy of tyrosine kinase inhibitors (TKIs) in lung cancer
patients with compound epidermal growth factor receptor (EGFR) mutations has not been …
patients with compound epidermal growth factor receptor (EGFR) mutations has not been …
[HTML][HTML] Clinical outcomes of lung adenocarcinoma patients harboring uncommon epidermal growth factor receptor (EGFR) mutations treated with EGFR-tyrosine …
J Si, X Gu, W Wang, S Ying… - Annals of Palliative …, 2022 - apm.amegroups.org
Background: This study aimed to explore the efficacy of different epidermal growth factor
receptor tyrosine kinase inhibitors (EGFR-TKIs) in lung adenocarcinoma (AC) patients …
receptor tyrosine kinase inhibitors (EGFR-TKIs) in lung adenocarcinoma (AC) patients …
相关搜索
- lung adenocarcinoma growth factor
- egfr tyrosine kinase inhibitor
- lung adenocarcinoma outcome for patients
- lung adenocarcinoma receptor tyrosine
- egfr tyrosine clinical outcomes
- kinase inhibitors clinical outcomes
- egfr mutation pulmonary adenocarcinoma
- lung adenocarcinoma progression patterns
- egfr mutation treatment timing
- lung adenocarcinoma meta regression
- egfr tyrosine associated factors
- associated factors kinase inhibitor
- treatment timing pulmonary adenocarcinoma
- lung adenocarcinoma tumor burden
- egfr tkis long term
- egfr mutations kinase inhibitor